Natera, Inc. $100 Million Follow-On Public Offering
Davis Polk advised the several underwriters in connection with the follow-on offering of 5,263,158 shares of common stock of Natera, Inc. for total gross proceeds of approximately $100…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Turning Point Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public offering of common stock of Turning Point Therapeutics, Inc…
Millendo Therapeutics, Inc. SEC-Registered At-The-Market Offering Program
Davis Polk advised a sales agent in connection with the establishments of an SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross…
NanoString Technologies, Inc. Follow-on Offering
Davis Polk advised the joint book-running managers and the lead manager in connection with a $119 million public offering of common stock by NanoString Technologies, Inc. The common…
Davis Polk Advises ShockWave Medical, Inc. on Its $111.4 Million Initial Public Offering
Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4…
Horizon Pharma Follow-On Offering
Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…
Medtronic Global Holdings S.C.A. €7 Billion Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €7 billion aggregate principal amount of notes by Medtronic Global…
Merck $5 Billion Notes Offering
Davis Polk advised the representatives of the underwriters in connection with the offering of $5.0 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…
Davis Polk Advises CStone Pharmaceuticals on Its HK$2.24 Billion (US$285.05 Million) Initial Public Offering
Davis Polk advised CStone Pharmaceuticals in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…
Eli Lilly $4.5 Billion Notes Offering
Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and Company of $1.15 billion aggregate principal amount of its 3.375%…